Core Viewpoint - The adjustment of U.S. tariffs will not have a significant adverse impact on the company's production and operations due to the low proportion of direct sales to U.S. customers and the strong dependency of the international market on Chinese raw materials [1] Group 1 - The company's direct sales to U.S. customers account for a low proportion of total revenue, indicating limited exposure to tariff changes [1] - The main products have weak substitutability, which strengthens the company's position in the market [1] - The international market's strong reliance on Chinese raw materials mitigates potential negative impacts from tariff adjustments [1] Group 2 - The company plans to implement pricing negotiation mechanisms to share potential cost pressures with customers [1] - There are plans to expand domestic sales and explore emerging markets to enhance risk resilience [1] Group 3 - The core products, Kexingdan and Mieqingdan, have received renewed approval from the EU, which is expected to aid in capacity release and performance growth [1]
广康生化：美国关税调整对公司生产经营不会产生重大不利影响